Instructions for Ursosan (Ursodeoxycholic acid) 250 mg 10 capsules
English product name
Ursosan
Release form
caps. 250 mg: 10, 50 or 100 pcs
tab, film coating, 500 mg: 10, 50 or 100 pcs
Description:
The tablets are coated with a film shell in white or almost white, are elongated and double-convex, with a groove on one side and a deep separating strip on the other side; The fracture is white or almost white.
1 tab.
ursodeoxycholic acid 500 mg
Auxiliary substances Ursosan:
cornstarch - 94.5 mg,
corn starch - 48 mg,
sodium carboxymethyl starch (type A) - 13 mg,
silicon dioxide colloidal - 15 mg,
magnesium stearate - 14.5 mg.
Shell Composition:
Opadray white 03B28796 - 5 mg (hypromellose 6 - 3.13 mg,
titanium dioxide - 1.56 mg,
macrogol 400 - 0.31 mg).
10 pcs - packages of box contour (1) - cardboard packs.
10 pcs - box-type contour (5) packages - cardboard packs.
10 pcs - box-type contouring packages (10) - cardboard packages.
ATC codes
A05AA02 Ursodeoxycholic acid
Clinical-pharmacological groups / Group affiliation
Hepatoprotector with cholelytic and cholelititic action
Active substance
ursodeoxycholic acid
Pharmacotherapy group Ursosan
Hepatoprotective agent
Storage Conditions
The tablets should be stored in a place protected from light at a temperature of 15° to 25°C.
Best before date Ursosan
The shelf life is three years.
The capsules should be stored in a dry, light-proof place at a temperature of 15° to 25°C.
Do not apply after expiry date.
The drug should be stored in a place inaccessible to children.
Pharmacological effect Ursosan:
Hepatoprotective drug. It also has cholelytic, hypolipidemic, hypocholesterolemic and immunomodulatory effects. Possessing high polar properties, ursodeoxycholic acid (UDHC) is incorporated into the hepatocyte, cholangiocyte and GI-CT epitheliocyte membrane, stabilizes its structure and protects the cell from the damaging effect of toxic bile acid salts, thereby reducing the cytotoxic effect thereof. It forms non-toxic mixed mycelles with lipophilic (toxic) bile acids, which reduces the ability of gastric reflux to damage cell membranes in cholestatic liver disease, biliary reflux gastritis, and reflux esophagitis.
Testimony Ursosan:
- uncomplicated gallstone disease: biliary sludge;
- dissolving cholesterol gallstones in a functioning gallbladder;
- prevention of recurrence of stone formation after cholecystectomy;
- chronic hepatitis of various origins (including toxic, medicinal);
- cholestatic diseases of the liver of various origins,
- including primary biliary cirrhosis (in the absence of signs of discompensation), primary sclerosing cholangitis, cystic
- fibrosis (cystic fibrosis);
- non-alcoholic fatty liver disease,
- including non-alcoholic steatohepatitis;
- alcoholic liver disease;
- chronic viral hepatitis;
- biliary dyskinesia;
- biliary reflux gastritis and reflux esophagitis.
Method of use, course and dosage Ursosan:
Take inside, during or after a meal, not chewing, drinking enough water.
To ensure the recommended dose, the tablet should be divided in half, breaking down at risk. Segments broken incorrectly should not be used. Holding a segment in the mouth tastes bitter.
For dissolving cholesterol gallstones, the average daily dose of the preparation is ten mg/kg (up to 12-15 mg/kg). Daily dose of the drug is taken once per night. The treatment course is six to twelve months or more until the stones are completely dissolved. If gallbladder stones are not reduced in size after twelve months of treatment, the drug should be discontinued.
For the prevention of the re-formation of stones, it is recommended to use the preparation for several months after the stones have dissolved.
For the prevention of repeated cholelitiasis after cholecystectomy, 250 mg (one cap or 1/2 tabb.) are prescribed twice daily for several months.
Application for kidney disorders
It is contraindicated in kidney failure.
Use in liver disorders
It is contraindicated in liver failure.
Terms of Sale Ursosan
The drug is prescription.
- Nosology (ICD codes)
- B15
- Acute hepatitis A
- B16
- Acute hepatitis B
- B17.1
- Acute hepatitis C
- B18.1
- Chronic viral hepatitis B without delta agent
- B18.2
- Chronic viral hepatitis C
- E84
- Cystic fibrosis
- K21.0
- Gastroesophageal reflux with esophagitis
- K30
- Functional dyspepsia (digestive disorder)
- K70
- Alcoholic liver disease
- K71
- Toxic liver failure
- K74
- Fibrosis and cirrhosis
- K80
- Gallstone disease [cholelitiasis] (incl. hepatic colic)
- K82.8
- Other refined diseases of the gallbladder and bubble duct (including dyskinesia)
- K83.0
- Holangit
- Z29.8
- Other specific preventive measures
